In the US, African American women have a significantly higher rate of mortality due to breast cancer compared to Caucasian American women. Molecular differences in tumor biology exist between racial groups; however, their contribution to cancer disparity is not well understood. Our studies have identified a race-specific, mechanistic link between microRNA-204 and the IGF2R. The IGF2R is a tumor suppressor gene in several cancers including breast cancer and IGF2R levels are found at significantly lower levels in African American women with breast cancer when compared to their Caucasian counterparts. We observed elevated levels of miR-204 in serum of African American women with breast cancer when compared to Caucasian American women and identified IGF2R as a direct target of miR-204. We show mechanistically that miR-204 mediated inhibition of IGF2R leads to activation of the IGF1R signaling pathway resulting in increased proliferation, migration and invasion, processes that are required for tumor progression. We developed a unique doxycycline-inducible miR-204 transgenic mouse model to define in vivo the oncogenic potential of miR-204 and the mechanism and functional consequences of IGF2R loss. We observed a significant increase in tumor growth and increased metastasis in these animals when compared to non-transgenic controls. This is the first characterization of miR-204 in an in vivo model. These data support a mechanism whereby miR-204 promotes tumor aggression through the IGF2-mediated hyperactivation of the IGF1R signaling pathway in response to direct negative regulation of the tumor suppressor IGF2R and that this could be a potential mechanism promoting breast cancer disparity.
INTRODUCTION Breast cancer (BC) is a worldwide health issue as it
represents the leading cause of cancer and remains the second leading cause of cancerrelated mortality in women. In the US, African American (AA) women have a significantly higher rate of BC mortality compared to Caucasian American (CA) women. Recent studies have highlighted the need for understanding the molecular basis of cancer disparities as these contribute to the observed differences in mortality that we observe in hormonally driven cancers (Albain et al., 2009 ).
The Insulin-like Growth Factor 2 Receptor (IGF2R) is a transmembrane receptor that binds Insulin-like Growth Factor (IGF-2), resulting in its degradation via internalization and transport to lysosomes (Oka et al., 1985) . Removal of IGF-2 from the extracellular environment precludes activation of the insulin-like growth factor 1 receptor (IGF1R); thus the IGF2R is believed to reduce the mitogenic effects of IGF-2. IGF2R is also involved in the activation of transforming growth factor beta (TGF-β) (Dennis and Rifkin, 1991) and may be a high affinity binding receptor for retinoic acid, an agent known to have diverse biological effects in both embryogenesis and oncogenesis (Kang et al., 1997) . Thus, important homeostatic controls regulating cell proliferation and apoptosis would be lost with the inactivation of IGF2R, suggesting that this receptor normally functions to inhibit tumor formation. Indeed, loss of heterozygosity (LOH) at the IGF2R locus has been reported in breast carcinomas, and somatic missense mutations of the remaining allele have altered ligand binding (Hu et al., 2006; Iwamoto et al., 2006; Tsujiuchi et al., 2004) . The IGF2R has been proposed to be a tumor suppressor gene given its antagonist role on cellular growth and evidence of LOH and loss-of-function mutations in several cancers including breast cancer (Chappell et al., 1997; Chen et al., 2002; Hankins et al., 1996; Oates et al., 1998) . More recently, studies have shown that reduced IGF2R expression correlates with poor patient prognosis in BC patients (Yu et al., 1996) and that decreased IGF2R expression may contribute to BC disparity (Kalla Singh et al., 2010) .
This study shows that circulating IGF2 levels, a potent mitogen that signals through the IGF1R, are higher in breast tissue from AA women when compared to CA women. They further went on to show that IGF2R levels were significantly lower in AA breast tumor samples, important as IGF2R acts as a non-signaling sink for IGF2 thereby preventing its pro-survival signaling function.
Importantly, IGF2 can also signal through the A isoform of the insulin receptor (IR-A) in many tumor types including breast cancer resulting in tumor promoting effects (Frasca et al., 1999; Ulanet et al., 2010) .
MicroRNAs (miRNAs) are small non-coding RNAs that are generally involved in the negative regulation of mRNA through seed sequences present within the 3'UTR of protein coding genes.
They have been studied in mammalian species for almost two decades and have been shown to be involved in most all cellular processes. Each miRNA has multiple targets and each 3'UTR can be targeted by multiple miRNAs. Understanding the regulation of these small molecules is complex; however, great strides have been made in a relatively short amount of time.
It should be noted that controversy surrounds the role of miR-204 in breast cancer , with some authors reporting miR-204 as a tumor suppressor (Imam et al., 2012; Li et al., 2014) and others, www.companyofscientists.com/index.php/chd e3
Cancer Health Disparities RESEARCH including our group, reporting it as an oncogenic miRNA or "oncomir" (Findlay et al., 2008 (Vimalraj et al., 2013) . A recent review details the dual nature of miR-204 in cancer (Li et al., 2016) .
This study describes a mechanistic link between miR-204 and a novel direct target IGF2R. We 
Materials and Methods

Cell Culture and Reagents
All cell lines were cultured and maintained at 37°C Immunohistochemistry IHC was performed as described (Guo et al., 2013) .
The Ki67 antibody was used at a 1:200 dilution.
Quantitative Real Time PCR
Total RNA from cell lines was extracted using the RNeasyPlus Mini Kit (Qiagen; Valencia, CA). qPCR was performed on a Roche Light Cycler 480 as previously described (Guo et al., 2013) . Primer sequences and UPL probe numbers are listed in 
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Transfection of cell lines
The cloning of miR-204 into pSuppressor-neo vector is already described (Findlay et al., 2008) . Cells were transfected with X-tremeGENE TM siRNA transfection reagent (Roche, Nutley, NJ).
Luciferase assays
The IGF2R 3′UTR luciferase reporter vector 
Western blot analysis
Cell lysate preparation and western blot analysis using enhanced chemiluminescence were performed as described previously (Findlay et al., 2008) . 
GAPDH (Santa Cruz
Biotechnology) was used as a loading control.
Transwell migration and invasion assay
Assays were performed as previously described (Guo et al., 2013) . Images were taken at a 40X objective for analysis.
Statistical analysis
Sample size for mouse experiments n ≥ 9. otherwise. Time to event outcomes were assessed using Kaplan-Meier curves and distributions compared between groups using the Peto-Peto test which is less sensitive to late differences than the traditional log rank test. For hypothesis testing, the alpha level was set at 0.05.
Results
miR-204 modulates migration and invasion in nontransformed and invasive breast cancer cell lines.
Our group has shown previously that overexpression of miR-204 was able to increase migration and invasion in the non-invasive breast cancer cell line MCF7 (Findlay et al., 2008 ( Figure 1F ) cells, similar to that observed in MCF7 cells (Findlay et al., 2008) . (2) the expression of both genes is driven by the same promoter, and (3) the expression of both genes is positively correlated both in vitro (Courboulin et al., 2011; Ying et al., 2013) and in vivo (Ding et al., 2015) . We found that in this dataset that could be examined by race, TRPM3 levels were higher in AA women when compared to CA women with breast cancer. Of interest, this dataset showed strikingly decreased levels of TRPM3 in women of Asian descent ( Figure 2C ).
IGF2R is a direct target of miR-204 in breast cancer cells and tissue
To 
IGF2 stimulates the IGF1R signaling pathway when IGF2R is inhibited by miR-204
IGF2 preferentially binds to the IGF2R; however, it is also known to act as an autocrine and paracrine cancers (Chung et al., 2012; Lam et al., 2011; Schultz et al., 2008; Xia et al., 2014) . However, with respect to hormonally driven cancers, e.g., prostate and breast, the story appears to be more complex. Our group and others have shown that miR-204 levels are significantly elevated in breast cancer samples compared to normal controls (Findlay et al., 2008; Mattie et al., 2006) . Published studies also suggest its role as a tumor suppressor in breast cancer ).
More recently, two studies were published by independent groups that support the role of miR-204 acting as an oncogene, or "oncomir", in cancer (Lee et al., 2016; Todorova et al., 2016) . The first was a study aimed at solving the controversy surrounding the seemingly opposing effects of miR-204 in breast cancer (Lee et al., 2016) . They 
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Reduced IGF2R expression correlates with poor patient prognosis in BC patients (Chappell et al., 1997; Hankins et al., 1996) , and a recent study 
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